BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

AI Summary: BridgeBio reported statistically significant Phase 3 results for infigratinib in achondroplasia, showing improved growth rates and body composition, moving the program toward an FDA filing. The readout strengthens BridgeBio’s rare-disease momentum and sets the stage for regulatory discussions and potential market entry.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA lifts holds on Intellia’s Phase 3 gene-editing trials / 2 months

FDA rejects Disc Medicine’s rare-disease drug despite priority review / 3 months

Axpaxli outperforms Eylea in Phase 3; FDA filing expected / 3 months

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval / 3 months

FDA Accepts Summit Therapeutics' Ivonescimab BLA for EGFR‑Mutant NSCLC / 4 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months